Anticancer agent 42 is an orally active anticancer agent with potent antitumor activity against MDA-MB-231 cells (IC50 = 0.07 μM); it exerts its anticancer effects by activating apoptotic pathways and p53 expression; it can be used in the research of metastatic breast cancer.